| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
|
Lancet Oncol
|
2011
|
7.10
|
|
2
|
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
|
Nat Rev Cancer
|
2009
|
6.28
|
|
3
|
Treatment of HER2-positive breast cancer: current status and future perspectives.
|
Nat Rev Clin Oncol
|
2011
|
4.12
|
|
4
|
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.
|
J Clin Oncol
|
2015
|
1.99
|
|
5
|
Targeting the ERBB family in cancer: couples therapy.
|
Nat Rev Cancer
|
2013
|
1.72
|
|
6
|
Current approaches and future directions in the treatment of HER2-positive breast cancer.
|
Cancer Treat Rev
|
2012
|
1.23
|
|
7
|
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.
|
Ann Oncol
|
2011
|
1.00
|
|
8
|
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.
|
Curr Oncol
|
2009
|
0.98
|
|
9
|
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.
|
BMC Med
|
2014
|
0.96
|
|
10
|
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.
|
Biochim Biophys Acta
|
2014
|
0.96
|
|
11
|
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
|
Lancet Oncol
|
2016
|
0.92
|
|
12
|
The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities.
|
Int J Proteomics
|
2011
|
0.78
|
|
13
|
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
|
Breast Care (Basel)
|
2015
|
0.77
|
|
14
|
Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
|
Breast Cancer Res
|
2009
|
0.77
|
|
15
|
Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.
|
Target Oncol
|
2016
|
0.75
|
|
16
|
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.
|
Ther Adv Med Oncol
|
2016
|
0.75
|